Martin Heidecker
Angel Investor @ AMR Action Fund
Martin Heidecker is a Series A investor at AMR Action Fund focused on Biotechnology and Health Care. Martin Heidecker - Managing Director @ Boehringer Ingelheim Venture Fund
- Total investments:
- 10
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Martin Heidecker invests in
Stages Martin Heidecker invests in
Countries Martin Heidecker invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (80%)
- Health Care 6 (60%)
- Medical 5 (50%)
- Therapeutics 4 (40%)
- Pharmaceutical 4 (40%)
Stage
- Series A 4 (40%)
- Series C 2 (20%)
- Seed 1 (10%)
- Series B 1 (10%)
- Series E 1 (10%)
Country
- United States 8 (80%)
- Switzerland 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $40M / Venture - Series Unknown / Aug 06, 2026 | ||
| Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M / Series E / Apr 25, 2023 | ||
| Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major globalhealth issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective. | $9M / Series C / Jan 05, 2023 | ||
| Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania. | $34M / Series C / Apr 04, 2022 | ||
| Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistantbacteria. | $20M / Series B / Apr 04, 2022 | ||
| Libra Therapeutics is a biotechnology company focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. | $29M / Series A / Sep 23, 2020 | ||
| Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its leadprograms and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts. | $20M / Seed / Apr 02, 2020 | ||
| Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extendtherapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States. | $12M / Series A / Apr 04, 2017 | ||
| Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include SentieonDNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation.The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California. | $3.8M / Series A / Apr 04, 2014 | ||
| ArmaGen is a developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies penetrate the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's, enabling patients suffering fromneurodegenerative disorders to get improved treatment. | $17M / Series A / Nov 29, 2012 |
Co-Investors
About AMR Action Fund
AMR Action Fund renders investment, healthcare, biotech, research and development, pharmaceutical, and antibiotic services. They invest in firms that are developing critical pathogen therapies and lobby for market reforms to transform how society values these lifesaving drugs. They aim to help launch two to four new antimicrobials over the nextdecade and build a sustainable investment environment.
AMR Action Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Henry Skinner
Chief Executive Officer
|
|||
Sergei Petukhov
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Martin Heidecker invest in?
Martin Heidecker invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Martin Heidecker?
Public channels for Martin Heidecker include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Martin Heidecker last invest?
The most recent investment recorded for Martin Heidecker closed in Aug 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
